vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $151.7M, roughly 1.9× Nutex Health, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 7.8%, a 88.5% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
ACAD vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $151.7M |
| Net Profit | $273.6M | $11.8M |
| Gross Margin | 90.8% | 30.4% |
| Operating Margin | 6.1% | 20.4% |
| Net Margin | 96.3% | 7.8% |
| Revenue YoY | 9.4% | -41.1% |
| Net Profit YoY | 90.3% | -80.8% |
| EPS (diluted) | $1.61 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $151.7M | ||
| Q3 25 | $278.6M | $267.8M | ||
| Q2 25 | $264.6M | $244.0M | ||
| Q1 25 | $244.3M | $211.8M | ||
| Q4 24 | $259.6M | $257.6M | ||
| Q3 24 | $250.4M | $78.8M | ||
| Q2 24 | $242.0M | $76.1M | ||
| Q1 24 | $205.8M | $67.5M |
| Q4 25 | $273.6M | $11.8M | ||
| Q3 25 | $71.8M | $55.4M | ||
| Q2 25 | $26.7M | $-17.7M | ||
| Q1 25 | $19.0M | $21.2M | ||
| Q4 24 | $143.7M | $61.6M | ||
| Q3 24 | $32.8M | $-8.8M | ||
| Q2 24 | $33.4M | $-364.0K | ||
| Q1 24 | $16.6M | $-364.0K |
| Q4 25 | 90.8% | 30.4% | ||
| Q3 25 | 92.2% | 57.8% | ||
| Q2 25 | 92.2% | 51.2% | ||
| Q1 25 | 91.7% | 55.9% | ||
| Q4 24 | 91.6% | 55.0% | ||
| Q3 24 | 92.5% | 27.8% | ||
| Q2 24 | 92.5% | 29.7% | ||
| Q1 24 | 88.8% | 15.1% |
| Q4 25 | 6.1% | 20.4% | ||
| Q3 25 | 12.8% | 48.7% | ||
| Q2 25 | 12.2% | 13.8% | ||
| Q1 25 | 7.9% | 38.1% | ||
| Q4 24 | 59.1% | 44.4% | ||
| Q3 24 | 12.6% | 12.3% | ||
| Q2 24 | 12.6% | 7.0% | ||
| Q1 24 | 7.4% | 2.1% |
| Q4 25 | 96.3% | 7.8% | ||
| Q3 25 | 25.8% | 20.7% | ||
| Q2 25 | 10.1% | -7.3% | ||
| Q1 25 | 7.8% | 10.0% | ||
| Q4 24 | 55.4% | 23.9% | ||
| Q3 24 | 13.1% | -11.2% | ||
| Q2 24 | 13.8% | -0.5% | ||
| Q1 24 | 8.0% | -0.5% |
| Q4 25 | $1.61 | $2.34 | ||
| Q3 25 | $0.42 | $7.76 | ||
| Q2 25 | $0.16 | $-2.95 | ||
| Q1 25 | $0.11 | $3.33 | ||
| Q4 24 | $0.86 | $11.56 | ||
| Q3 24 | $0.20 | $-1.72 | ||
| Q2 24 | $0.20 | $-0.07 | ||
| Q1 24 | $0.10 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $329.4M |
| Total Assets | $1.6B | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $185.6M | ||
| Q3 25 | $258.0M | $166.0M | ||
| Q2 25 | $253.6M | $96.7M | ||
| Q1 25 | $217.7M | $84.7M | ||
| Q4 24 | $319.6M | $40.6M | ||
| Q3 24 | $155.1M | $46.9M | ||
| Q2 24 | $177.1M | $40.8M | ||
| Q1 24 | $204.7M | $30.0M |
| Q4 25 | $1.2B | $329.4M | ||
| Q3 25 | $917.3M | $317.2M | ||
| Q2 25 | $822.4M | $235.3M | ||
| Q1 25 | $765.2M | $176.9M | ||
| Q4 24 | $732.8M | $132.4M | ||
| Q3 24 | $577.2M | $60.4M | ||
| Q2 24 | $516.7M | $62.7M | ||
| Q1 24 | $464.0M | $63.0M |
| Q4 25 | $1.6B | $918.5M | ||
| Q3 25 | $1.3B | $964.5M | ||
| Q2 25 | $1.2B | $841.0M | ||
| Q1 25 | $1.1B | $761.9M | ||
| Q4 24 | $1.2B | $655.3M | ||
| Q3 24 | $976.9M | $438.5M | ||
| Q2 24 | $914.1M | $422.4M | ||
| Q1 24 | $855.1M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $70.4M |
| Free Cash FlowOCF − Capex | — | $69.0M |
| FCF MarginFCF / Revenue | — | 45.5% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $70.4M | ||
| Q3 25 | $74.3M | $99.5M | ||
| Q2 25 | $64.0M | $27.3M | ||
| Q1 25 | $20.3M | $51.0M | ||
| Q4 24 | $40.4M | $54.0K | ||
| Q3 24 | $63.2M | $6.8M | ||
| Q2 24 | $25.0M | $13.3M | ||
| Q1 24 | $29.1M | $3.1M |
| Q4 25 | — | $69.0M | ||
| Q3 25 | $73.9M | $99.2M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $-341.0K | ||
| Q3 24 | $63.2M | $6.2M | ||
| Q2 24 | — | $12.7M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | — | 45.5% | ||
| Q3 25 | 26.5% | 37.0% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 24.0% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | 25.2% | 7.8% | ||
| Q2 24 | — | 16.7% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | -0.18× | 5.95× | ||
| Q3 25 | 1.03× | 1.80× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | 2.40× | ||
| Q4 24 | 0.28× | 0.00× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
